Saniona recently presented positive results from the open-label extension study with tesomet in Prader-Willi Syndrome (PWS) patients. This also marks the completion of the phase IIa study. In this interview, CEO Jørgen Drejer summarizes the most important data points from the phase IIa trial, and how they plan to move forward in PWS.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se